Mandate

Vinge has advised Corline Biomedical AB (publ) in connection with a directed share issue

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Corline intends to use the issue proceeds to continue the development of Renaparin® in phase 2 clinical development to interim data, build the organisation to increase proceeds to the medical technology branch, improve the financial flexibility and strengthen the working capital.

Vinge’s team has consisted of Dain Hård Nevonen, Amanda Knutsson and Clara Sohlberg.

Related

Vinge advises Spotlight Group in connection with offer from Kriptown

Vinge is advising Spotlight Group AB (publ) in connection with Kriptown SAS having made a public cash takeover offer to the shareholders of Spotlight Group.
June 17, 2026

Vinge has advised EQT IX in connection with its exit of Beijer Ref AB (publ)

Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of series B in Beijer Ref AB (publ) through an accelerated bookbuilding process carried out on 15 June 2026.
June 16, 2026

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson to Citira, a European tire management provider and portfolio company of Norvestor. Headquartered in Stockholm, Malte Månson is an independent service and repair provider for commercial vehicles and operates a network of 28 service workshop locations across Sweden, authorized by brands such as MAN, DAF, IVECO, Mercedes-Benz, Setra, VDL and EVO. Malte Månson has an annual revenue of SEK 800 million and employs over 300 full-time professionals.
June 08, 2026